Abstract
Objective. Recently, multicomponent quality-of-life indicators have become increasingly important in monitoring the health status of patients with hypertension and evaluating the effectiveness of treatment. Improving patient quality of life is considered one of the key objectives of the medical intervention.
Methods. To assess the quality of life of patients with, we used the standardized SF-36 (Short Form-36 Health Survey) questionnaire, which allows to explicitly examine the respondent physical and psycho-emotional status.
Results. We analyzed the association between polymorphisms of endothelial nitric oxide (NO) synthase (eNOS) (NOS3, T786C) and angiotensin II receptor type 1 (AGTR1, A1166C) genes and quality of life. Patients with polymorphisms associated with lower intravascular pressure had lower baseline QoL scores, particularly on the “physical functioning” and “general health” scales (p<0.05). Patients with heterozygous or homozygous “unfavorable” genotypes (AGTR1_CC, NOS3_CC) have significantly lower total indicators of both physical and psycho-emotional health compared to patients with “better” genotypes (AA, TT) and the control group.
Conclusion. Patients with polymorphisms that cause reduced bioavailability of NO or excessive activation of AGRT1 show a significant deterioration in quality of life on all key SF-36 scales. This indicates the significant role of genetic factors in shaping the subjective perception of health in patients with arterial hypertension.